X
Company profile: Evidera
https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/data-disruption-and-applying-enabled-intelligence/
RWE
Orphan drugs: overcoming barriers to market access
What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Is the NHS ready to use real-world evidence to treat cancer?
Is NHS ready to use real-world data to find new therapies and ways to bring drugs to patients?
Utilise medtech for optimum care management
Medtech companies can provide the tools to empower patients and HCPs.
Healthcare evidence development: guilty until proven innocent?
Pharma must prepare its case meticulously to support its new drug applications.
Behind the buzz of real-world data and real-world evidence
Putting the who, where and why of real-world studies into context.
Integrating patient insights and real-world data: the future of drug development
Drugs development in 2017 looks very different to how it did 10 years ago, and it’s still evolving.
A new age: the real-world development pathway
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Outcomes-based medicine demands real-world evidence
RWE must become a fundamental accompaniment to traditional RCT data.
1 2
